Related Experiment Video
Updated: Oct 10, 2025

09:11
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
21.8K
An Approach for Live Motion Correction for TRUS-MR Prostate Fusion Biopsy using Deep Learning
Summary
This study introduces an AI framework for prostate biopsies, improving alignment between MRI and ultrasound images. The system corrects for patient movement and tissue deformation, enhancing accuracy and speed for live procedures.
Area of Science:
- Medical Imaging
- Artificial Intelligence
- Biomedical Engineering
Background:
- Prostate biopsy accuracy is limited by alignment challenges between pre-operative MRI and live TRUS.
- Patient movement and probe pressure cause prostate deformation, impacting image registration.
- Efficient and accurate MR-TRUS alignment is crucial for effective fusion-guided biopsies.
Purpose of the Study:
- To develop a deep learning framework for real-time, accurate alignment in TRUS-MR fusion guided prostate biopsies.
- To simultaneously correct for rigid motion and prostate deformation during live biopsy procedures.
- To reduce computation time and improve the efficiency of MR-TRUS image registration.
Main Methods:
- An end-to-end deep learning network was designed for integrated rigid and deformation correction.
- The framework was trained and validated using 6500 images from 34 subjects.
- The registration pipeline was evaluated on an unseen patient dataset.
Main Results:
- The proposed pipeline achieved a Target Registration Error (TRE) of 2.51 mm after correction.
- The system demonstrated a computation time of 70ms, enabling a rendering rate of 14 FPS.
- The framework is well-suited for live TRUS-MR alignment in clinical settings.
Conclusions:
- The developed deep learning framework significantly improves TRUS-MR image alignment accuracy and efficiency.
- Real-time correction of rigid motion and deformation enhances the reliability of fusion-guided prostate biopsies.
- This technology offers a valuable tool to reduce false negative rates in prostate cancer diagnosis.

